Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)
ID: 354719Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $6M

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354719

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-012.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a non-competitive funding opportunity for the continuation of the Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D), specifically targeting research at the University of Pennsylvania. This cooperative agreement aims to support a team of investigators in collecting and characterizing pancreatic tissues from patients with Type 1 Diabetes (T1D) and age-matched controls, while also analyzing and sharing the resulting data through the PANC DB open-access resource database. The program is crucial for advancing understanding of T1D mechanisms and enhancing collaborative research efforts within the Human Islet Research Network. The funding amount is up to $5.5 million, with a project period of up to four years, and applications are due by October 24, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-25-012-Full-Announcement.html
    RFA-DK-25-012.html
    The National Institutes of Health (NIH) is soliciting applications for a non-competitive funding opportunity aimed at renewing the Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D), specifically targeting research at the University of Pennsylvania. The program focuses on studying human pancreatic tissues to enhance understanding of the causes and mechanisms of Type 1 Diabetes (T1D). Key objectives include collecting and characterizing pancreatic tissues from T1D patients and age-matched controls, analyzing tissue data, and sharing outcomes through the PANC DB database. The renewal emphasizes continuity in data collection, the incorporation of new technologies, and collaborative efforts within the Human Islet Research Network. Applicants are required to adhere to detailed submission instructions, and a single award of up to $7.5 million is planned for a maximum project period of four years. The opportunity highlights the importance of systematic data generation and the establishment of partnerships to enhance research insights into T1D. Compliance with strict application guidelines is mandatory to ensure successful submission and integration of their findings into the broader scientific community.
    Similar Opportunities
    Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition Funding Opportunity titled "Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers" (T1DAPC-CCs), aimed at establishing a clinical consortium to study diabetes incidence following acute pancreatitis episodes, with a focus on type 1 diabetes. This initiative seeks applications from previously funded Clinical Centers to continue a longitudinal observational study that investigates the incidence, etiology, and risk factors associated with diabetes emerging after acute pancreatitis, emphasizing collaboration among consortium members and effective data collection strategies. The funding amount is capped at $350,000 annually, with a project timeline extending up to five years, and applications are due by November 19, 2024, with the earliest anticipated award start in July 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for a cooperative agreement to establish the Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC). The primary objective is to conduct a longitudinal observational study, known as the DREAM study, which will investigate the incidence and mechanisms of diabetes that develop following episodes of acute pancreatitis. This initiative is crucial for understanding the relationship between acute pancreatitis and the onset of diabetes, particularly type 1 diabetes, and aims to identify genetic and environmental risk factors in a diverse population. Interested applicants must submit their proposals by November 19, 2024, with a funding ceiling of $800,000, and can direct inquiries to grantsinfo@nih.gov for further information.
    Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)," aimed at establishing Recruitment Sites (RS) for enrolling individuals with Type 1 diabetes (T1D) who are at risk of nephropathy. This initiative seeks applications for a longitudinal cohort study that will involve obtaining kidney biopsies and conducting comprehensive clinical phenotyping, with a focus on ethical practices and inclusivity to enhance understanding of T1D nephropathy and identify potential therapeutic targets. The funding opportunity has a budget of approximately $1.3 million, with individual awards of up to $400,000 in direct costs annually, and key deadlines include a letter of intent due on November 11, 2024, with applications closing on December 10, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for a cooperative agreement aimed at advancing research on Type 1 Diabetic nephropathy (T1D). This initiative seeks applications from Recruitment Sites (RS) to enroll adult and pediatric patients with T1D, particularly those at high risk for diabetic nephropathy, into a longitudinal cohort study, which will include protocol-based kidney biopsies. The research will leverage existing resources from the Kidney Precision Medicine Project (KPMP) to create a Kidney Tissue Atlas, identify disease subgroups, and explore novel therapeutic targets. The estimated total program funding for this opportunity is $1.3 million, with the NOFO expected to be published in fall 2024 and applications due in late fall 2024. Interested applicants are encouraged to reach out to the NIDDK contacts provided in the announcement for further information.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Resource for Human Organs and Tissues" through a cooperative agreement mechanism (U42), aimed at supporting a program that provides and facilitates the availability of human tissues and organs for biomedical research. The initiative seeks to enhance the procurement, preservation, and distribution of diverse biospecimens, both normal and diseased, to aid researchers in understanding various diseases and addressing public health priorities. Applicants must demonstrate a proven track record in managing a human tissue and organ research resource, with direct costs capped at $720,000 over a potential five-year project period. The application period opens on December 24, 2024, with a submission deadline of September 25, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed)" aimed at developing informatics tools that enhance the use of a human pangenome reference as part of the Human Genome Reference Program (HGRP). The initiative seeks to fund projects that create broadly applicable tools for various sectors of genomics, including clinical and functional genomics, with a focus on improving analytical capabilities over existing methods. Up to $4 million will be allocated to support approximately six projects over a maximum period of three years, with individual project budgets capped at $400,000 annually. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for March 3, 2025.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.